In Vivo and In Vitro Assay to Address Dendritic Cell Antigen Cross-Presenting Capacity

Area of Science:

• Immunology
• Cell Biology
• Cancer Research

Background:

• Antigen cross-presentation by dendritic cells is vital for initiating CD8+ T cell responses.
• This process is critical for effective anti-tumor immunity mediated by cytotoxic T lymphocytes (CTLs).
• Current assays often use model antigens like ovalbumin (OVA) and OVA-specific T cells.

Purpose of the Study:

• To establish and validate novel in vivo and in vitro assays for measuring antigen cross-presentation.
• To assess the functional capacity of dendritic cells in presenting cell-associated antigens.
• To provide reliable methods for studying immune responses in cancer and infectious diseases.

Main Methods:

• Development of in vivo assays to evaluate cross-presentation within a living organism.
• Establishment of in vitro assays using cell-associated ovalbumin (OVA) as a model antigen.
• Utilization of OVA-specific TCR transgenic CD8+ T (OT-I) cells to quantify cross-presenting capacity.

Main Results:

• Demonstrated successful implementation of both in vivo and in vitro assays for antigen cross-presentation.
• Quantified the functional capacity of dendritic cells to cross-present cell-associated OVA.
• Validated the use of OT-I cells as effective reporters for cross-presentation efficiency.

Conclusions:

• The described assays provide robust tools for studying dendritic cell function in antigen cross-presentation.
• These methods are applicable to understanding immune responses in various pathologies, including cancer.
• The assays facilitate research into strategies for enhancing anti-tumor CTL responses.